CLAIMS

1. A peptide comprising one of the following FVIII-derived sequences:

PRCLTRYYSSFVNME
VEDNIMVTFRNQASR
DNIMVTFRNQASRPY
IMVTFRNQASRPYSF
MVTFRNQASRPYSFY
VTFRNQASRPYSFYS
TKSDPRCLTRYYSSF
KSDPRCLTRYYSSFV
SDPRCLTRYYSSFVN
DPRCLTRYYSSFVNM
RCLTRYYSSFVNMER
CLTRYYSSFVNMERD
PPIIARYIRLHPTHY
PIIARYIRLHPTHYS
IARYIRLHPTHYSIR
ARYIRLHPTHYSIRS

with one or more of the following modifications:

(i) removal of one or more hydophobic amino acid(s);

(ii) replacement of one or more hydrophobic amino acid(s) with charged hydrophilic amino acid(s); and

(iii) insertion of a charged amino acid at one or both terminus(i)

which modified peptide is capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell.

2. A peptide according to claim 1, which comprises the sequence EDNIMVTFRNQASR.

3. A peptide according to claim 1 or 2, which consists of the sequence EDNIMVTFRNQASR.

4. A composition comprising a plurality of peptides, including one or more peptide(s) according to any preceding claim.

5. A peptide according to any of claims 1 to 3, or a composition according to claim 4, for use in suppressing or preventing the production of factor VIII inhibitor antibodies *in vivo*.

6. The use of a peptide according to any of claims 1 to 3, or a composition according to claim 4, in the manufacture of a medicament to suppress or prevent the production of factor VIII inhibitor antibodies *in vivo*.

7. The use of a peptide according to any of claims 1 to 3, or a composition according to claim 4 in the manufacture of a medicament for suppressing or preventing the production of factor VIII inhibitor antibodies in a subject.

8. The use of a peptide according to any of claims 1 to 3, or a composition according to claim 4 in the manufacture of a medicament for treating haemophilia in a subject.

9. The use according to claim 7 or 8, wherein the subject has haemophilia A, and is undergoing, or is about to undergo, factor VIII replacement therapy.

10. The use according to claim 8 or 9, wherein the subject has, or is at risk from contracting, acquired haemophilia.

11. The use according to any of claims 7 to 10, wherein the subject is HLA-DR2.

CLAIMS

1. A peptide which consists of the sequence EDNIMVTFRNQASR.

2. A composition comprising a plurality of peptides, including a peptide according to claim 1.

3. A peptide according to claim 1, or a composition according to claim 2, for use in treating haemophilia in a subject.

4. A peptide according to claim 1 or composition according to claim 2 for use in treating haemophilia in a subject according to claim 3, wherein the subject

(a) has haemophilia A, and is undergoing, or is about to undergo, factor VIII replacement therapy; or

(b) has, or is at risk from contracting, acquired haemophilia.

5. A peptide according to claim 1 or composition according to claim 2 for use in treating haemophilia in a subject according to claim 3, wherein the subject is HLA-DR2.